Literature DB >> 26985306

Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.

Molly D Congdon1, Yugesh Kharel2, Anne M Brown1, Stephanie N Lewis1, David R Bevan1, Kevin R Lynch2, Webster L Santos3.   

Abstract

The two isoforms of sphingosine kinase (SphK1 and SphK2) are the only enzymes that phosphorylate sphingosine to sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in a broad range of cellular processes including migration, proliferation, and inflammation. SphKs are targets for various diseases such as cancer, fibrosis, and Alzheimer's and sickle cell disease. Herein, we disclose the structure-activity profile of naphthalene-containing SphK inhibitors and molecular modeling studies that reveal a key molecular switch that controls SphK selectivity.

Entities:  

Keywords:  Sphingosine; molecular docking; sphingosine kinase; sphingosine-1-phosphate; structure−activity relationship

Year:  2016        PMID: 26985306      PMCID: PMC4789682          DOI: 10.1021/acsmedchemlett.5b00304

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

Review 1.  Sphingosine 1-phosphate, a key cell signaling molecule.

Authors:  Sarah Spiegel; Sheldon Milstien
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

2.  Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.

Authors:  Mithun R Raje; Kenneth Knott; Yugesh Kharel; Philippe Bissel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2011-11-15       Impact factor: 3.641

Review 3.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

4.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde.

Authors:  Noriko Takuwa; Wa Du; Erika Kaneko; Yasuo Okamoto; Kazuaki Yoshioka; Yoh Takuwa
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

5.  Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.

Authors:  Molly D Congdon; Elizabeth S Childress; Neeraj N Patwardhan; James Gumkowski; Emily A Morris; Yugesh Kharel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem Lett       Date:  2015-03-23       Impact factor: 2.823

6.  BACE1 activity is modulated by cell-associated sphingosine-1-phosphate.

Authors:  Nobumasa Takasugi; Tomoki Sasaki; Kunimichi Suzuki; Satoko Osawa; Hayato Isshiki; Yukiko Hori; Naoaki Shimada; Takuya Higo; Satoshi Yokoshima; Tohru Fukuyama; Virginia M-Y Lee; John Q Trojanowski; Taisuke Tomita; Takeshi Iwatsubo
Journal:  J Neurosci       Date:  2011-05-04       Impact factor: 6.167

7.  Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

Authors:  Barbara Zemann; Bernd Kinzel; Matthias Müller; Roland Reuschel; Diana Mechtcheriakova; Nicole Urtz; Frédéric Bornancin; Thomas Baumruker; Andreas Billich
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

8.  Crystal Structure of Sphingosine Kinase 1 with PF-543.

Authors:  Jing Wang; Stefan Knapp; Nigel J Pyne; Susan Pyne; Jonathan M Elkins
Journal:  ACS Med Chem Lett       Date:  2014-10-27       Impact factor: 4.345

9.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

10.  Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.

Authors:  Kevin J French; Yan Zhuang; Lynn W Maines; Peng Gao; Wenxue Wang; Vladimir Beljanski; John J Upson; Cecelia L Green; Staci N Keller; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2010-01-08       Impact factor: 4.030

View more
  7 in total

1.  Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.

Authors:  Elizabeth S Childress; Yugesh Kharel; Anne M Brown; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2017-04-25       Impact factor: 7.446

2.  In Silico Characterization of Structural Distinctions between Isoforms of Human and Mouse Sphingosine Kinases for Accelerating Drug Discovery.

Authors:  Brittney L Worrell; Anne M Brown; Webster L Santos; David R Bevan
Journal:  J Chem Inf Model       Date:  2019-03-19       Impact factor: 4.956

3.  Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.

Authors:  Molly Congdon; Russell G Fritzemeier; Yugesh Kharel; Anne M Brown; Vlad Serbulea; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  Eur J Med Chem       Date:  2020-12-29       Impact factor: 6.514

4.  Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study.

Authors:  Lubabah A Mousa; Ma'mon M Hatmal; Mutasem Taha
Journal:  J Comput Aided Mol Des       Date:  2022-01-21       Impact factor: 3.686

5.  A Novel Sphingosine Kinase Inhibitor Suppresses Chikungunya Virus Infection.

Authors:  Opeoluwa O Oyewole; Kyle Dunnavant; Shaurav Bhattarai; Yugesh Kharel; Kevin R Lynch; Webster L Santos; St Patrick Reid
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

6.  Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity.

Authors:  Christopher D Sibley; Emily A Morris; Yugesh Kharel; Anne M Brown; Tao Huang; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2020-01-28       Impact factor: 7.446

7.  Lipophilic tail modifications of 2-(hydroxymethyl)pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors.

Authors:  Hao Li; Christopher D Sibley; Yugesh Kharel; Tao Huang; Anne M Brown; Laura G Wonilowicz; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2020-12-13       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.